Christopher Jacquinot
Optometrist · Pittsburg, KSNPI 1003016361
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,452 of the $3,919 with a category attached, or 88.1%. It is spread thinly across 18 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $29.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$583
- Johnson & Johnson Vision Care, Inc.$579
- Alcon$452
- Sight Sciences, Inc.$391
- Novartis$362
- Tarsus Pharmaceuticals, Inc.$315
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$46712%
- Food & beverage$3,45288%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 8 | $583 |
| Johnson & Johnson Vision Care, Inc. | 18 | $579 |
| Alcon | 21 | $452 |
| Sight Sciences, Inc. | 4 | $391 |
| Novartis | 10 | $362 |
| Tarsus Pharmaceuticals, Inc. | 15 | $315 |
| Sun Pharmaceutical Industries Inc. | 8 | $247 |
| AbbVie(2 entities) | 13 | $241 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $183 |
| Bausch & Lomb Americas Inc. | 9 | $143 |
| Osmotica Pharmaceutical Corp. | 1 | $136 |
| Dompe US, Inc. | 3 | $125 |
| Kala Pharmaceuticals, Inc. | 5 | $76 |
| Shire North American Group Inc | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Glaukos Corporation | 1 | $19 |
| Maculogix, Inc. | 1 | $14 |
| ABB Con-cise Optical Group LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$467
- TRYPTYR$150
- TearCare SmartLid$149
- TEARCARE(TM) (2.2) SYSTEM KIT$149
- Acuvue$138
- XIIDRA$125
- OMNI(R) SURGICAL SYSTEM (US)$114
- TearCare$108
How this compares
$3,919 in reported general payments places this provider in the 90th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 29 | $52,556 |
| RestasisCyclosporine | 34 | $33,309 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,566 |
| VyzultaLatanoprostene Bunod | 17 | $9,020 |
| LumiganBimatoprost | 19 | $8,960 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,015 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $4,035 |
| Brimonidine Tartrate | 42 | $2,994 |
| Latanoprost | 303 | $2,063 |
| Travoprost | 13 | $1,433 |
| Loteprednol Etabonate | 16 | $1,035 |
| Prednisolone Acetate | 17 | $600 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $405 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $375 |
| Timolol Maleate | 24 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $315 | $52,55629 claims |
| AbbVieRestasis, Lumigan, Combigan | $241 | $46,30469 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $143 | $19,58631 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $183 | $1,03516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 optometrist providers in Kansas.
Other optometrist in Pittsburg
- Shane KannarrPittsburg$529K
- Jeffry GersonOlathe$619K
- Jason PingelMission$244K
- Justin WeigelOlathe$220K
- Chad ThompsonBeloit$96K
- Brandon HunterLeawood$68K
- Raymond BrillMission$19K
- Vincent PennipedeOverland Park$16K
- Ryan WineingerShawnee$13K
- Diana CarrigerTopeka$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.